GlassScriptPhysician profile
Mohamed Tom
NPI 1801102587
$12,569.84
in general payments reported to CMS, 2019-2025
21 companies · $8,206 in 2025
The $8,206 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $128 · 2021: $595 · 2022: $116 · 2023: $2,747 · 2024: $149 · 2025: $8,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $6,300 · Travel and Lodging: $2,998 · Food and Beverage: $1,804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $6,300.00 |
| Travel and Lodging | $2,998.04 |
| Food and Beverage | $1,804.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $8,393.52 | 2021-2025 | Xcopri |
| Livanova USA, INC. | $2,159.27 | 2021-2023 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Dixi Medical USA Corp | $728.76 | 2023 | |
| Ucb, INC. | $291.11 | 2019-2024 | Fintepla |
| Greenwich Biosciences, INC. | $190.44 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $165.40 | 2019 | |
| Abbvie INC. | $153.19 | 2023-2025 | Ubrelvy, Qulipta |
| Biohaven Pharmaceuticals, INC. | $104.50 | 2021 | |
| Sunovion Pharmaceuticals INC. | $84.66 | 2019-2020 | |
| Amgen INC. | $76.93 | 2019 | |
| Amneal Pharmaceuticals LLC | $29.26 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $24.37 | 2019 | |
| Acorda Therapeutics, INC | $23.08 | 2019 | |
| Eisai INC. | $22.03 | 2019 | |
| Alexion Pharmaceuticals, INC. | $21.88 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $19.86 | 2019 | |
| Lundbeck LLC | $19.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.61 | 2019 | |
| Acadia Pharmaceuticals INC | $15.57 | 2020 | |
| Vertical Pharmaceuticals, LLC | $13.96 | 2019 | |
| Promius Pharma LLC | $13.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Tom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.